Pomerantz LLP investigates Anika Therapeutics securities fraud claims.

Pomerantz LLP is investigating claims against Anika Therapeutics, Inc. regarding potential securities fraud or unlawful business practices. The investigation concerns the company's announcement of topline results from a clinical trial of Hyalofast, a resorbable hyaluronic acid scaffold used for cartilage repair, which did not meet pre-specified co-primary endpoints. Investors who held Anika shares are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

Pomerantz LLP has initiated an investigation into potential securities fraud or unlawful business practices by Anika Therapeutics, Inc. (NASDAQ: ANIK) on behalf of its investors. The investigation centers around the company's recent announcement of topline results from a pivotal clinical trial of Hyalofast, a resorbable hyaluronic acid scaffold used in conjunction with autologous bone marrow aspirate concentrate (BMAC) for cartilage repair.

On July 30, 2025, Anika Therapeutics issued a press release detailing the results of the U.S. pivotal clinical trial. While Hyalofast demonstrated consistent improvements in treated patients across all measures of pain and function relative to microfracture, the study did not meet its pre-specified co-primary endpoints. The press release attributed this failure to a higher subject dropout rate in the microfracture arm and missed visits during the COVID-19 pandemic, which resulted in missing data and a reduced evaluable sample size, complicating the statistical analysis.

The announcement led to a significant drop in Anika's stock price. On July 30, 2025, the stock fell by $3.06 per share, or 27.42%, to close at $8.10 per share.

Pomerantz LLP, a renowned firm in corporate, securities, and antitrust class litigation, is investigating whether Anika and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. Investors who held Anika shares are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is recognized for its work in the areas of corporate, securities, and antitrust class litigation. The firm has a history of recovering multimillion-dollar damages awards on behalf of class members. For more information, visit www.pomlaw.com.

References:
[1] https://www.marketscreener.com/news/pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-anika-therapeutics-inc-anik-ce7c51dfda8aff23
[2] https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-anika-therapeutics-inc---anik-302527428.html